Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Pfizer Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings, including current portion of long-term debt 4.57 1.49 1.23 1.75 9.67
Trade accounts payable 2.96 3.45 3.07 2.79 2.52
Dividends payable 1.05 1.17 1.24 1.40 1.26
Income taxes payable 1.04 0.80 0.70 0.68 0.59
Accrued compensation and related items 1.23 1.73 1.84 1.98 1.62
Deferred revenues 1.19 1.28 1.69 0.72 0.00
Other current liabilities 9.07 11.44 13.74 7.47 6.62
Current liabilities 21.10% 21.37% 23.51% 16.81% 22.27%
Long-term debt, excluding current portion 27.17 16.68 19.94 24.08 21.47
Pension and postretirement benefit obligations 0.96 1.14 2.05 3.51 4.04
Noncurrent deferred tax liabilities 0.28 0.52 0.19 2.63 3.33
Other taxes payable 3.77 4.98 6.24 7.50 7.24
Other noncurrent liabilities 7.30 6.68 5.37 4.32 3.77
Noncurrent liabilities 39.48% 29.99% 33.80% 42.04% 39.85%
Total liabilities 60.58% 51.36% 57.32% 58.84% 62.12%
Preferred stock, no par value, at stated value 0.00 0.00 0.00 0.00 0.01
Common stock, $0.05 par value 0.21 0.24 0.26 0.30 0.28
Additional paid-in capital 40.90 46.55 49.92 57.50 52.20
Treasury stock, shares at cost -50.55 -57.79 -61.36 -71.96 -66.15
Retained earnings 52.25 63.72 56.97 62.74 58.31
Accumulated other comprehensive loss -3.51 -4.21 -3.25 -7.58 -6.95
Total Pfizer Inc. shareholders’ equity 39.30% 48.51% 42.54% 41.00% 37.70%
Equity attributable to noncontrolling interests 0.12 0.13 0.14 0.15 0.18
Total equity 39.42% 48.64% 42.68% 41.16% 37.88%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Pfizer Inc. current liabilities as a percentage of total liabilities and equity decreased from 2021 to 2022 and from 2022 to 2023.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Pfizer Inc. noncurrent liabilities as a percentage of total liabilities and equity decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pfizer Inc. total liabilities as a percentage of total liabilities and equity decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Total Pfizer Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Pfizer Inc. total Pfizer Inc. shareholders’ equity as a percentage of total liabilities and equity increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.